Submissions from 2023
Characterizing the experience of sensitive skin: A pilot survey, Erika T. McCormick, Dillon Nussbaum, Alana Sadur, Sapana Desai, and Adam Friedman
Insights from a joint pediatric dermatology-gynecology vulvar clinic: A retrospective study, Nikita Menta, Dillon Nussbaum, Aneka Khilnani, Tazim Dowlut-McElroy, and Kaiane A. Habeshian
The (one-year) prevalence of atopic dermatitis in Brazil: A population-based telephone survey, Hélio Amante Miot, Valeria Aoki, Raquel Leão Orfali, Dirceu Solé, Márcia Carvalho Mallozi, Tatiane C. Rodrigues, and Jonathan I. Silverberg
Treatment preferences among patients with mild-to-moderate atopic dermatitis, Kelley Myers, Jonathan I. Silverberg, Shreekant Parasuraman, Anna Pierce, Lawrence F. Eichenfield, and Christine Poulos
Safety of Oral Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis, Shanthi Narla and Jonathan I. Silverberg
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials, Amy S. Paller, Jonathan I. Silverberg, Michael J. Cork, Emma Guttman-Yassky, Benjamin Lockshin, Alan D. Irvine, Moon Bum Kim, Kenji Kabashima, Zhen Chen, Yufang Lu, Ashish Bansal, Ana B. Rossi, and Arsalan Shabbir
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials, Amy S. Paller, Jonathan I. Silverberg, Michael J. Cork, Emma Guttman-Yassky, Benjamin Lockshin, Alan D. Irvine, Moon Bum Kim, Kenji Kabashima, Zhen Chen, Yufang Lu, Ashish Bansal, Ana B. Rossi, and Arsalan Shabbir
Association of vitiligo and inflammatory arthropathy in hospitalized US adults, Kevin R. Patel, Amanda M. Justiz, Ammar M. Ahmed, and Jonathan I. Silverberg
National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicine, Natalia Pelet Del Toro, Rayan Yahia, Steven R. Feldman, Abby Van Voorhees, Lawrence Green, Sergio Schwartzman, Evan Siegel, Kelly M. Cordoro, Seemal R. Desai, Leon Kircik, Wilson Liao, Jason E. Hawkes, Jeffrey Weinberg, John Koo, Elizabeth Brezinski Wallace, Leah M. Howard, April Armstrong, and George Han
Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials, Hannah Penton, Sayeli Jayade, Santhani Selveindran, Marieke Heisen, Christophe Piketty, Liliana Ulianov, Zarif K. Jabbar-Lopez, Jonathan I. Silverberg, and Jorge Puelles
A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30 EADV Congress 2021, Andreas Pinter, Linda Stein Gold, Adam Reich, Lawrence J. Green, Morten Praestegaard, Johan Selmer, April W. Armstrong, Anne Danø, Sunil Dhawan, Jordi Galván, Sandra E. Stallknecht, Paw Trebbien, and Matthias Augustin
Facial atopic dermatitis is associated with sensitization to cow's milk, egg whites, and peanuts in children under 36 months, Meredith Tyree Polaskey, Anne Bendelow, Janak Mukherji, Brooke Buranosky, Jonathan I. Silverberg, and Anna Fishbein
Associations Between Shower and Moisturizing Practices with Atopic Dermatitis Severity: A Prospective Longitudinal Cohort Study, Uros Rakita, Trisha Kaundinya, and Jonathan I. Silverberg
Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe, Margo J. Reeder, Erin Warshaw, Srikanth Aravamuthan, Donald V. Belsito, Johannes Geier, Mark Wilkinson, Amber Reck Atwater, Ian R. White, Jonathan I. Silverberg, James S. Taylor, Joseph F. Fowler, Howard I. Maibach, Joel G. DeKoven, Timo Buhl, Nina Botto, Ana Maria Giménez-Arnau, Rosella Gallo, Christen Mowad, Claudia C. Lang, Vincent A. DeLeo, Graham Johnston, Melanie D. Pratt, Knut Brockow, Brandon L. Adler, Marie-Claude Houle, Heinrich Dickel, Marie Louise Schuttelaar, JiaDe Yu, Radoslaw Spiewak, Cory Dunnick, Francesca Larese Filon, and Skaidra Valiukeviciene
More than just methylisothiazolinone: Retrospective analysis of patients with isothiazolinone allergy in North America, 2017-2020, Margo J. Reeder, Donglin Zhang, Srikanth R. Aravamuthan, Erin M. Warshaw, Joel G. DeKoven, Jonathan I. Silverberg, Brandon L. Adler, Amber R. Atwater, James S. Taylor, Marie-Claude Houle, Donald V. Belsito, Jiade Yu, Nina Botto, Christen M. Mowad, Cory A. Dunnick, Vincent A. DeLeo, and Melanie D. Pratt
Higher Levels of Response on Clinical Atopic Dermatitis Severity Measures Are Associated with Meaningful Improvements in Patient-Reported Symptom and Quality of Life Measures: Integrated Analysis of Three Upadacitinib Phase 3 Trials, K Reich, M S. de Bruin-Weller, M Deleuran, B M. Calimlim, N Chen, X Hu, A R. Tenorio, and J I. Silverberg
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3, Kristian Reich, Eric Simpson, Andreas Wollenberg, Robert Bissonnette, Masatoshi Abe, Tracy Cardillo, Jonathan Janes, Luna Sun, Sherry Chen, and Jonathan I. Silverberg
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study, K Reich, J I. Silverberg, K A. Papp, M Deleuran, N Katoh, B Strober, L A. Beck, M de Bruin-Weller, T Werfel, F Zhang, P Biswas, M D. DiBonaventura, G Chan, S A. Farooqui, U Kerkmann, and C Clibborn
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study, K Reich, J I. Silverberg, K A. Papp, M Deleuran, N Katoh, B Strober, L A. Beck, M de Bruin-Weller, T Werfel, F Zhang, P Biswas, M D. DiBonaventura, G Chan, S Johnson, S A. Farooqui, U Kerkmann, and C Clibborn
Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis, Yael Renert-Yuval, Ester Del Duca, Bernd Arents, Robert Bissonnette, Aaron M. Drucker, Carsten Flohr, Emma Guttman-Yassky, Dirkjan Hijnen, Kenji Kabashima, Yael A. Leshem, Amy S. Paller, Jonathan I. Silverberg, Eric L. Simpson, Phyllis Spuls, Christian Vestergaard, Andreas Wollenberg, Alan D. Irvine, and Jacob P. Thyssen
Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study, Jorge A. Rios-Duarte, Maria J. Sanchez-Zapata, and Jonathan I. Silverberg
Association of Adult Atopic Dermatitis Severity With Bacterial, Viral, and Fungal Skin Infections, Jorge A. Rios-Duarte and Jonathan I. Silverberg
Assessment and Management of Sleep Disturbances in Atopic Dermatitis: A Review, Archana Samynathan, Anna B. Fishbein, Sabra M. Abbott, Genery D. Booster, Phyllis C. Zee, Stephen H. Sheldon, Gil Yosipovitch, and Jonathan I. Silverberg
Navigating the Atopic Dermatitis Toolbox: Challenging Scenarios and Shared Decision Making, Archana Samynathan and Jonathan I. Silverberg
Severe reactive infectious mucocutaneous eruption mimicking drug-induced epidermal necrolysis triggered by norovirus, Eric Sanfilippo, Kaiane Habeshian, Colleen H. Cotton, and Anna Yasmine Kirkorian
Assessment of racial and ethnic differences of atopic dermatitis severity and treatment patterns in a diverse outpatient cohort in the United States: a retrospective observational study, Eric Sanfilippo, Sneha Iyer, Nisha Patel, and Jonathan I. Silverberg
Venous Thromboembolism in Patients With Bullous Pemphigoid, Maria C. Schneeweiss, Joseph F. Merola, Richard Wyss, Jonathan I. Silverberg, and Arash Mostaghimi
Executive Summary: American Academy of Dermatology Guidelines of care for the management of atopic dermatitis in adults with topical therapies, Robert Sidbury, Ali Alikhan, Lionel Bercovitch, David E. Cohen, Jennifer M. Darr, Aaron M. Drucker, Lawrence F. Eichenfield, Lindsy Frazer-Green, Amy S. Paller, Kathryn Schwarzenberger, Jonathan I. Silverberg, Anne Marie Singh, Peggy A. Wu, and Dawn M. Davis
Guidelines of care for the management of atopic dermatitis in adults with topical therapies, Robert Sidbury, Ali Alikhan, Lionel Bercovitch, David E. Cohen, Jennifer M. Darr, Aaron M. Drucker, Lawrence F. Eichenfield, Lindsy Frazer-Green, Amy S. Paller, Kathryn Schwarzenberger, Jonathan I. Silverberg, Anne Marie Singh, Peggy A. Wu, and Dawn M. Davis
Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines, Elaine C. Siegfried, Lisa M. Arkin, Yvonne E. Chiu, Adelaide A. Hebert, Jeffrey P. Callen, Leslie Castelo-Soccio, Dominic O. Co, Kelly M. Cordoro, Megan L. Curran, Austin M. Dalrymple, Carsten Flohr, Ken B. Gordon, Diane Hanna, Alan D. Irvine, Susan Kim, A Yasmine Kirkorian, Irene Lara-Corrales, Jill Lindstrom, Amy S. Paller, Melissa Reyes, Wendy Smith Begolka, Wynnis L. Tom, Abby S. Van Voorhees, Ruth Ann Vleugels, Lara Wine Lee, Olivia M. Davies, and Heather A. Brandling-Bennett
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids, Jonathan I. Silverberg, April Armstrong, Andrew Blauvelt, and Kristian Reich
Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE), Jonathan I. Silverberg, Robert Bissonnette, Leon Kircik, Dedee F. Murrell, Andrew Selfridge, Kris Liu, Gurpreet Ahluwalia, and Emma Guttman-Yassky
Tapinarof Validates the Aryl Hydrocarbon Receptor as a Therapeutic Target: A Clinical Review, Jonathan I. Silverberg, Mark Boguniewicz, Francisco J. Quintana, Rachael A. Clark, Lara Gross, Ikuo Hirano, Anna M. Tallman, Philip M. Brown, Doral Fredericks, David S. Rubenstein, and Kimberly A. McHale
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis, Jonathan I. Silverberg, Marjolein de Bruin-Weller, Brian M. Calimlim, Xiaofei Hu, Sarah A. Ofori, Andrew M. Platt, Henrique D. Teixeira, Kilian Eyerich, and Jacob P. Thyssen
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis, Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaçi, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia-Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar G. Pillai, and Julien Seneschal
Development of an Eczema Area and Severity Index Atlas for Diverse Skin Types, Jonathan I. Silverberg, Joshua Horeczko, and Andrew Alexis
A Mini Review of the Impact of Baseline Disease Severity on Clinical Outcomes: Should We Compare Atopic Dermatitis Clinical Trials?, Jonathan I. Silverberg, Selwyn Ho, and Raúl Collazo
Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS), Jonathan I. Silverberg, Yael A. Leshem, Brian M. Calimlim, Jeffrey McDonald, and Leighann Litcher-Kelly
Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS), Jonathan I. Silverberg, Yael A. Leshem, Brian M. Calimlim, Jeffrey McDonald, and Leighann Litcher-Kelly
Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial, Jonathan I. Silverberg, Peter A. Lio, Eric L. Simpson, Connie Li, Daniel R. Brownell, Ioannis Gryllos, Judith Ng-Cashin, Todd Krueger, Victoria R. Swaidan, Robin L. Bliss, and Hyun D. Kim
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials, Jonathan I. Silverberg, Charles W. Lynde, Katrina Abuabara, Cataldo Patruno, Anna de Benedetto, Haixin Zhang, Ryan B. Thomas, Gaëlle Bégo-Le-Bagousse, Faisal A. Khokhar, Jignesh Vakil, Ainara Rodríguez Marco, and Noah A. Levit
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient Survey, Jonathan I. Silverberg, Jennifer A. Mohawk, Joshua Cirulli, Kristine Nograles, Joseph C. Punzalan, Kevin M. Kelly, Brian S. Kim, Emma Guttman-Yassky, and Mark Lebwohl
Patch Testing With Nickel, Cobalt, and Chromium in Patients With Suspected Allergic Contact Dermatitis, Jonathan I. Silverberg, Nisha Patel, Erin M. Warshaw, Joel G. DeKoven, Donald V. Belsito, Amber R. Atwater, James S. Taylor, Denis Sasseville, Margo J. Reeder, Marie-Claude Houle, Vincent A. DeLeo, Howard I. Maibach, Joseph F. Fowler, Kathryn A. Zug, Melanie D. Pratt, JiaDe Yu, Christen M. Mowad, Nina C. Botto, and Brandon L. Adler
Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry, Jonathan I. Silverberg, Evangeline Pierce, Meghan Feely, Amber Reck Atwater, Amy Schrader, Eric A. Jones, Swapna S. Dave, and Eric L. Simpson
Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry, Jonathan I. Silverberg, Vivian Y. Shi, Andrew Alexis, Evangeline Pierce, Angel Cronin, Robert R. McLean, Carla Roberts-Toler, Maria J. Rueda, Amber R. Atwater, and Eric Simpson
Prevalence and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: A Cross Sectional Study from the TARGET-DERM AD Cohort, Jonathan I. Silverberg, Brenda Simpson, Katrina Abuabara, Emma Guttman-Yassky, Brian Calimlim, Colleen Wegzyn, Whitney Krueger, Amy Gamelli, Breda Munoz, Rachel W. Faller, Julie M. Crawford, Ayman Grada, and Lawrence F. Eichenfield
Narrative Review of the Pathogenesis of Stasis Dermatitis: An Inflammatory Skin Manifestation of Venous Hypertension, Jonathan Silverberg, J Mark Jackson, Robert S. Kirsner, Roni Adiri, Gary Friedman, Xing-Hua Gao, Steven D. Billings, and Urs Kerkmann
Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition, Eric L. Simpson, Emma Guttman-Yassky, Lawrence F. Eichenfield, Mark Boguniewicz, Thomas Bieber, Shannon Schneider, Adriana Guana, and Jonathan I. Silverberg
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial, Eric L. Simpson, Jonathan I. Silverberg, Jacob P. Thyssen, Manuelle Viguier, Diamant Thaçi, Marjolein de Bruin-Weller, Stephan Weidinger, Gary Chan, Marco DiBonaventura, Pinaki Biswas, Claire Feeney, Christopher Koulias, and Michael J. Cork
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial, Eric L. Simpson, Jonathan I. Silverberg, Jacob P. Thyssen, Manuelle Viguier, Diamant Thaçi, Marjolein de Bruin-Weller, Stephan Weidinger, Gary Chan, Marco DiBonaventura, Pinaki Biswas, Claire Feeney, Christopher Koulias, and Michael J. Cork
Outpatient utilization patterns for atopic dermatitis in the United States, Partik Singh and Jonathan I. Silverberg
Correlation of clinician-reported outcomes with patient-reported outcomes by race and ethnicity in patients with atopic dermatitis, Jourdan Hydol Smith and Jonathan I. Silverberg
Largest comparative analysis: Novel large spot size 595 nm, high-energy, pulsed dye laser reduces number of treatments for improvement of adult and pediatric port wine birthmarks, Pooja Sodha, Jordan V. Wang, Nader Aboul-Fettouh, Katherine Martin, Roy G. Geronemus, and Paul M. Friedman
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study, Howard Sofen, Robert Bissonnette, Gil Yosipovitch, Jonathan I. Silverberg, Stephen Tyring, Wei Jing Loo, Matthew Zook, Mark Lee, Liangxing Zou, Guang-Liang Jiang, and John F. Paolini
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study, Howard Sofen, Robert Bissonnette, Gil Yosipovitch, Jonathan I. Silverberg, Stephen Tyring, Wei Jing Loo, Matthew Zook, Mark Lee, Liangxing Zou, Guang-Liang Jiang, and John F. Paolini
Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials, Jeffrey L. Sugarman, Adelaide Hebert, John C. Browning, Amy S. Paller, Stephen Stripling, Lawrence J. Green, Martina Cartwright, Carolyn Enloe, Nick Wells, and Tomoko Maeda-Chubachi
Comorbidities of atopic dermatitis-what does the evidence say?, Jacob P. Thyssen, Anne-Sofie Halling, Peter Schmid-Grendelmeier, Emma Guttman-Yassky, and Jonathan I. Silverberg
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study, Karen A. Veverka, Steven T. Thng, Jonathan I. Silverberg, April W. Armstrong, Josemund Menezes, Alexandre Kaoukhov, and Andrew Blauvelt
Patch Testing to Chlorhexidine Digluconate, 1% Aqueous: North American Contact Dermatitis Group Experience, 2015-2020, Erin M. Warshaw, Joohee Han, Sara A. Kullberg, Joel G. DeKoven, Brandon L. Adler, Jonathan I. Silverberg, Marie-Claude Houle, Melanie D. Pratt, Donald V. Belsito, Jiade Yu, Nina C. Botto, Margo J. Reeder, James S. Taylor, Amber R. Atwater, Cory A. Dunnick, Vincent A. DeLeo, and Chris M. Mowad
Patch Testing to Paraphenylenediamine: The North American Contact Dermatitis Group Experience (1994-2018), Erin M. Warshaw, Malina Yamashita Peterson, Amber R. Atwater, Joel G. DeKoven, Melanie D. Pratt, James S. Taylor, Donald V. Belsito, Jonathan I. Silverberg, Margo J. Reeder, Vincent A. DeLeo, Marie-Claude Houle, Cory A. Dunnick, Jiade Yu, Brandon Adler, Christen Mowad, and Nina C. Botto
Long-term Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5%, in Rosacea: Results From an Extension of Two Phase III, Vehicle-controlled Trials, William P. Werschler, Jeffrey Sugarman, Neal Bhatia, Hilary Baldwin, Lawrence J. Green, Ori Nov, Vered Ram, Ofra Levy-Hacham, and Linda Stein Gold
Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management, Gil Yosipovitch, Susan T. Nedorost, Jonathan I. Silverberg, Adam J. Friedman, Juliana M. Canosa, and Amy Cha
Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management, Gil Yosipovitch, Susan T. Nedorost, Jonathan I. Silverberg, Adam J. Friedman, Juliana M. Canosa, and Amy Cha
Patch Test Results Among Older Adults: A Retrospective Analysis of the North American Contact Dermatitis Group Data (2009-2020), JiaDe Yu, Hadley Johnson, Joel G. DeKoven, Erin M. Warshaw, James S. Taylor, Donald V. Belsito, Brandon L. Adler, Jonathan I. Silverberg, Amber R. Atwater, Margo J. Reeder, Nina Botto, Marie-Claude Houle, Christen M. Mowad, Melanie D. Pratt, and Cory A. Dunnick
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial, Matthew J. Zirwas, Zoe D. Draelos, Janet DuBois, Leon H. Kircik, Angela Y. Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence J. Green, Scott T. Guenthner, Laura K. Ferris, Seth B. Forman, Steven E. Kempers, Edward Lain, Charles W. Lynde, David M. Pariser, Darryl P. Toth, Paul S. Yamauchi, Robert C. Higham, David Krupa, Patrick Burnett, and David R. Berk
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial, Matthew J. Zirwas, Zoe D. Draelos, Janet DuBois, Leon H. Kircik, Angela Y. Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence J. Green, Scott T. Guenthner, Laura K. Ferris, Seth B. Forman, Steven E. Kempers, Edward Lain, Charles W. Lynde, David M. Pariser, Darryl P. Toth, Paul S. Yamauchi, Robert C. Higham, David Krupa, Patrick Burnett, and David R. Berk
Submissions from 2022
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort, Katrina Abuabara, Lawrence F. Eichenfield, Robert Bissonnette, Jonathan I. Silverberg, Jerry Bagel, Emma Guttman-Yassky, Diamant Thaci, Eric L. Simpson, John E. Harris, James Krueger, Daniela E. Myers, Amy Gamelli, Marina Milutinovic, Anne Parneix, Julie M. Crawford, Breda Munoz, and Amy S. Paller
Benign Familial Pemphigus, Nagasai C. Adusumilli and Adam J. Friedman
Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region, Milan J. Anadkat, Mario Lacouture, Adam Friedman, Zachary D. Horne, Jae Jung, Benjamin Kaffenberger, Sujith Kalmadi, Liza Ovington, Rupesh Kotecha, Huda Ismail Abdullah, and Federica Grosso
Shoe Allergens: A Retrospective Analysis of Cross-sectional Data From the North American Contact Dermatitis Group, 2005-2018, Amber Reck Atwater, Raina Bembry, Cynthia L. Green, Joel G. DeKoven, Erin M. Warshaw, Donald V. Belsito, Howard I. Maibach, Jonathan I. Silverberg, James S. Taylor, Margo J. Reeder, Kathryn A. Zug, Joseph F. Fowler, Melanie D. Pratt, Denis Sasseville, and Vincent A. DeLeo
Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE, Layla Bakaa, Jeffrey M. Pernica, Rachel J. Couban, Kelly Jo Tackett, Craig N. Burkhart, Liz Leins, Joanne Smart, Maria Teresa Garcia-Romero, Itzel Guadalupe Elizalde-Jiménez, Michael Herd, Rachel Netahe Asiniwasis, Mark Boguniewicz, Anna De Benedetto, Lina Chen, Kathy Ellison, Winfred Frazier, Matthew Greenhawt, Joey Huynh, Jennifer LeBovidge, Mary Laura Lind, Peter Lio, Monica O'Brien, Peck Y. Ong, Jonathan I. Silverberg, Jonathan M. Spergel, Julie Wang, Wendy Smith Begolka, Lynda Schneider, and Derek K. Chu
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional Study, Sebastien Barbarot, Jonathan I. Silverberg, Abhijit Gadkari, Eric L. Simpson, Stephan Weidinger, Paola Mina-Osorio, Ana B. Rossi, Lysel Brignoli, Tarek Mnif, Isabelle Guillemin, Miriam C. Fenton, Marine Pellan, Puneet Mahajan, Dimittri Delevry, Ashish Bansal, and Laurent Eckert
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary, Thomas Bieber, Eric L. Simpson, Jonathan I. Silverberg, Diamant Thaçi, Carle Paul, Andrew E. Pink, Yoko Kataoka, Chia-Yu Chu, Marco DiBonaventura, Ricardo Rojo, Jeremias Antinew, Ileana Ionita, Rodney Sinclair, Seth Forman, Jacek Zdybski, Pinaki Biswas, Bimal Malhotra, Fan Zhang, and Hernan Valdez
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3, Andrew Blauvelt, Melinda Gooderham, Neal Bhatia, Richard G. Langley, Shannon Schneider, John Zoidis, Azra Kurbasic, April Armstrong, and Jonathan I. Silverberg
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis, Andrew Blauvelt, Leon Kircik, Kim A. Papp, Eric L. Simpson, Jonathan I. Silverberg, Brian S. Kim, Shawn G. Kwatra, Michael E. Kuligowski, May E. Venturanza, Shaoceng Wei, and Jacek C. Szepietowski
Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream: Pooled Analysis From Two Randomized Phase 3 Studies, Andrew Blauvelt, Jacek C. Szepietowski, Kim Papp, Eric L. Simpson, Jonathan I. Silverberg, Brian S. Kim, Shawn G. Kwatra, Michael E. Kuligowski, May E. Venturanza, Shaoceng Wei, and Leon Kircik
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies, Lisa Bloudek, Lawrence F. Eichenfield, Jonathan I. Silverberg, Vijay N. Joish, Jennifer H. Lofland, Kang Sun, Matthias Augustin, Kristen Migliaccio-Walle, and Sean D. Sullivan
Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity, Otavio Cabral-Marques, Gilad Halpert, Lena F. Schimke, Yuri Ostrinski, Aristo Vojdani, Gabriela Crispim Baiocchi, Paula Paccielli Freire, Igor Salerno Filgueiras, Israel Zyskind, Miriam T. Lattin, Florian Tran, Stefan Schreiber, Alexandre H. Marques, Desirée Rodrigues Plaça, Dennyson Leandro Fonseca, Jens Y. Humrich, Antje Müller, Lasse M. Giil, Hanna Graßhoff, Anja Schumann, Alexander Hackel, Juliane Junker, Carlotta Meyer, Hans D. Ochs, Yael Bublil Lavi, Carmen Scheibenbogen, Ralf Dechend, Igor Jurisica, Kai Schulze-Forster, Jonathan I. Silverberg, Howard Amital, and Jason Zimmerman
Longitudinal course and predictors of depressive symptoms in atopic dermatitis, Sheena Chatrath, Donald Lei, Muhammad Yousaf, Rajeev Chavda, Sylvie Gabriel, and Jonathan I. Silverberg
Atopic Dermatitis Is Associated With Lower Patient Satisfaction in US Adults, Brian T. Cheng and Jonathan I. Silverberg
Financial burden and impact of atopic dermatitis out-of-pocket healthcare expenses among black individuals in the United States, Raj Chovatiya, Wendy Smith Begolka, Isabelle J. Thibau, and Jonathan I. Silverberg
Impact and Associations of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States, Raj Chovatiya, Wendy Smith Begolka, Isabelle J. Thibau, and Jonathan I. Silverberg
DESCRIBE-AD: A novel classification framework for atopic dermatitis, Raj Chovatiya and Jonathan I. Silverberg
Evaluating the longitudinal course of atopic dermatitis: A review of the literature, Raj Chovatiya and Jonathan I. Silverberg
Evaluating the Longitudinal Course of Atopic Dermatitis: Implications for Clinical Practice, Raj Chovatiya and Jonathan I. Silverberg
Iatrogenic Burden of Atopic Dermatitis, Raj Chovatiya and Jonathan I. Silverberg
Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries, Joel J. Credle, Jonathan Gunn, Puwanat Sangkhapreecha, Daniel R. Monaco, Xuwen Alice Zheng, Hung-Ji Tsai, Azaan Wilbon, William R. Morgenlander, Andre Rastegar, Yi Dong, Sahana Jayaraman, Lorenzo Tosi, Biju Parekkadan, Alan N. Baer, Mario Roederer, Evan M. Bloch, Aaron A. Tobian, Israel Zyskind, Jonathan I. Silverberg, Avi Z. Rosenberg, Andrea L. Cox, Tom Lloyd, Andrew L. Mammen, and H Benjamin Larman
AAD Guidelines: awareness of comorbidities associated with atopic dermatitis in adults, Dawn M. Davis, Aaron M. Drucker, Ali Alikhan, Lionel Bercovitch, David E. Cohen, Jennifer M. Darr, Lawrence F. Eichenfield, Lindsy Frazer-Green, Amy S. Paller, Jonathan I. Silverberg, Anne Marie Singh, and Robert Sidbury
Sleep impairment in patients with chronic inflammatory skin diseases: A review of mechanisms and management, Grace Y. Duan and Jonathan I. Silverberg
An intertriginous eruption in an infant, Adaora Ewulu, Michael A. Cardis, and Kaiane A. Habeshian
1,550 nm Erbium-Doped and 1,927 nm Thulium Nonablative Fractional Laser System: Best Practices and Treatment Setting Recommendations, Paul M. Friedman, Jeffrey S. Dover, Anne Chapas, Zakia Rahman, Edward V. Ross, Suzanne L. Kilmer, Wendy E. Roberts, Pooja Sodha, Julie B. Stimmel, Mary Beth Moncrief, and Jill S. Waibel
Clinical features and eosinophilia in pityriasis rubra pilaris: A multicenter cohort, Shilpa Ghatnekar, Nidhi Shah, Michelle S. Min, Daniel R. Mazori, Avery H. LaChance, Ruth Ann Vleugels, and Vinod E. Nambudiri
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial, Melinda J. Gooderham, Giampiero Girolomoni, Julian O. Moore, Jonathan I. Silverberg, Robert Bissonnette, Seth Forman, Elena Peeva, Pinaki Biswas, Hernan Valdez, and Gary Chan
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial, Melinda J. Gooderham, Giampiero Girolomoni, Julian O. Moore, Jonathan I. Silverberg, Robert Bissonnette, Seth Forman, Elena Peeva, Pinaki Biswas, Hernan Valdez, and Gary Chan
Enhancing Topical Pharmacotherapy for Acne and Rosacea: Vehicle Choices and Outcomes, Lawrence J. Green, Edward Lain, Thomas Prunty, and Robert Rhoades
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma, Neil D. Gross, David M. Miller, Nikhil I. Khushalani, Vasu Divi, Emily S. Ruiz, Evan J. Lipson, Friedegund Meier, Yungpo B. Su, Paul L. Swiecicki, Jennifer Atlas, Jessica L. Geiger, Axel Hauschild, Jennifer H. Choe, Brett G. Hughes, Dirk Schadendorf, Vishal A. Patel, Jade Homsi, Janis M. Taube, Annette M. Lim, Renata Ferrarotto, Howard L. Kaufman, Frank Seebach, Israel Lowy, Suk-Young Yoo, Melissa Mathias, Keilah Fenech, Hyunsil Han, Matthew G. Fury, and Danny Rischin
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma, Neil D. Gross, David M. Miller, Nikhil I. Khushalani, Vasu Divi, Emily S. Ruiz, Evan J. Lipson, Friedegund Meier, Yungpo B. Su, Paul L. Swiecicki, Jennifer Atlas, Jessica L. Geiger, Axel Hauschild, Jennifer H. Choe, Brett G. Hughes, Dirk Schadendorf, Vishal A. Patel, Jade Homsi, Janis M. Taube, Annette M. Lim, Renata Ferrarotto, Howard L. Kaufman, Frank Seebach, Israel Lowy, Suk-Young Yoo, Melissa Mathias, Keilah Fenech, Hyunsil Han, Matthew G. Fury, and Danny Rischin
Clinical Efficacy of a Digital Intervention for Patients with Atopic Dermatitis: a Prospective Single-Center Study, Sigrídur Lára Gudmundsdóttir, Tommaso Ballarini, María L. Ámundadóttir, Judit Mészáros, Jenna H. Eysteinsdóttir, Ragna H. Thorleifsdóttir, Sigrídur K. Hrafnkelsdóttir, Heida B. Bragadóttir, Saemundur Oddsson, and Jonathan I. Silverberg
Clinical Efficacy of a Digital Intervention for Patients with Atopic Dermatitis: a Prospective Single-Center Study, Sigrídur Lára Gudmundsdóttir, Tommaso Ballarini, María L. Ámundadóttir, Judit Mészáros, Jenna H. Eysteinsdóttir, Ragna H. Thorleifsdóttir, Sigrídur K. Hrafnkelsdóttir, Heida B. Bragadóttir, Saemundur Oddsson, and Jonathan I. Silverberg
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies, Emma Guttman-Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, Kim A. Papp, Amy S. Paller, Stephan Weidinger, H Chih-Ho Hong, Barbara Hendrickson, Deanne Dilley, Allan R. Tenorio, Barry Ladizinski, Alvina D. Chu, John Liu, and Alan D. Irvine